These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34062264)

  • 21. m
    Zhang C; Ou S; Zhou Y; Liu P; Zhang P; Li Z; Xu R; Li Y
    Front Oncol; 2021; 11():696371. PubMed ID: 34458141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The RNA m6A writer METTL14 in cancers: Roles, structures, and applications.
    Zhou H; Yin K; Zhang Y; Tian J; Wang S
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188609. PubMed ID: 34375716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advancing on pancreatic cancer.
    Nat Rev Gastroenterol Hepatol; 2021 Jul; 18(7):447. PubMed ID: 34188210
    [No Abstract]   [Full Text] [Related]  

  • 24. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer.
    Byrne KT; Betts CB; Mick R; Sivagnanam S; Bajor DL; Laheru DA; Chiorean EG; O'Hara MH; Liudahl SM; Newcomb C; Alanio C; Ferreira AP; Park BS; Ohtani T; Huffman AP; Väyrynen SA; Dias Costa A; Kaiser JC; Lacroix AM; Redlinger C; Stern M; Nowak JA; Wherry EJ; Cheever MA; Wolpin BM; Furth EE; Jaffee EM; Coussens LM; Vonderheide RH
    Clin Cancer Res; 2021 Aug; 27(16):4574-4586. PubMed ID: 34112709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade.
    Nielsen SR; Strøbech JE; Horton ER; Jackstadt R; Laitala A; Bravo MC; Maltese G; Jensen ARD; Reuten R; Rafaeva M; Karim SA; Hwang CI; Arnes L; Tuveson DA; Sansom OJ; Morton JP; Erler JT
    Nat Commun; 2021 Jun; 12(1):3414. PubMed ID: 34099731
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Maddalena M; Mallel G; Nataraj NB; Shreberk-Shaked M; Hassin O; Mukherjee S; Arandkar S; Rotkopf R; Kapsack A; Lambiase G; Pellegrino B; Ben-Isaac E; Golani O; Addadi Y; Hajaj E; Eilam R; Straussman R; Yarden Y; Lotem M; Oren M
    Proc Natl Acad Sci U S A; 2021 Jun; 118(23):. PubMed ID: 34088837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models.
    Hoare O; Fraunhoffer N; Elkaoutari A; Gayet O; Bigonnet M; Roques J; Nicolle R; McGuckin C; Forraz N; Sohier E; Tonon L; Wajda P; Boyault S; Attignon V; Tabone-Eglinger S; Barbier S; Mignard C; Duchamp O; Iovanna J; Dusetti NJ
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34069519
    [No Abstract]   [Full Text] [Related]  

  • 28. Prognostic Model Construction of Disulfidptosis-Related Genes and Targeted Anticancer Drug Research in Pancreatic Cancer.
    Duan H; Gao L; Asikaer A; Liu L; Huang K; Shen Y
    Mol Biotechnol; 2024 Apr; ():. PubMed ID: 38575817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PELI1: key players in the oncogenic characteristics of pancreatic Cancer.
    Fei X; Zhu C; Liu P; Liu S; Ren L; Lu R; Hou J; Gao Y; Wang X; Pan Y
    J Exp Clin Cancer Res; 2024 Mar; 43(1):91. PubMed ID: 38528516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EPYC functions as a novel prognostic biomarker for pancreatic cancer.
    Yang Z; Li H; Hao J; Mei H; Qiu M; Wang H; Gao M
    Sci Rep; 2024 Jan; 14(1):719. PubMed ID: 38184732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic challenges.
    Jiang Z; Zheng X; Li M; Liu M
    Front Med; 2023 Dec; 17(6):1135-1169. PubMed ID: 38151666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Developments and challenges in neoadjuvant therapy for locally advanced pancreatic cancer.
    Zhou B; Zhang SR; Chen G; Chen P
    World J Gastroenterol; 2023 Sep; 29(35):5094-5103. PubMed ID: 37744290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A more radical perspective on surgical approach and outcomes in pancreatic cancer-a narrative review.
    Fernandes ESM; de Mello FPT; Braga EP; de Souza GO; Andrade R; Pimentel LS; Girão CL; Siqueira M; Moraes-Junior JMA; de Oliveira RV; Goldaracena N; Torres OJM
    J Gastrointest Oncol; 2023 Aug; 14(4):1964-1981. PubMed ID: 37720458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CSTF2T facilitates pancreatic adenocarcinoma growth and metastasis by elevating H3K4Me1 methylation of CALB2 via ASH2L.
    Liu W; Hu D; Li J; Xu Q; Chen Z; Xu B
    Cancer Biol Ther; 2023 Dec; 24(1):2216041. PubMed ID: 37287122
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current Approaches for the Curative-Intent Surgical Treatment of Pancreatic Ductal Adenocarcinoma.
    Słodkowski M; Wroński M; Karkocha D; Kraj L; Śmigielska K; Jachnis A
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37174050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of cuproptosis-related lncRNA signature for predicting prognosis and tumor immune microenvironment in pancreatic cancer.
    Yao HF; Xu DP; Zheng JH; Xu Y; Jia QY; Zhu YH; Yang J; He RZ; Ma D; Yang MW; Fu XL; Liu DJ; Huo YM; Yang JY; Zhang JF
    Apoptosis; 2023 Aug; 28(7-8):1090-1112. PubMed ID: 37079192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation.
    Lin C; Li T; Wang Y; Lai S; Huang Y; Guo Z; Zhang X; Weng S
    Cell Death Dis; 2023 Mar; 14(3):221. PubMed ID: 36977668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. JNK inhibitor IX restrains pancreatic cancer through p53 and p21.
    Shi J; Yang X; Kang Q; Lu J; Denzinger M; Kornmann M; Traub B
    Front Oncol; 2022; 12():1006131. PubMed ID: 36568248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic, Diagnostic, and Clinicopathological Significance of Circular RNAs in Pancreatic Cancer: A Systematic Review and Meta-Analysis.
    Li J; Ye Z; Hu X; Hou S; Hang Q
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-Term Effect of Pancreaticoduodenectomy Combined with Revascularization for Resectable Pancreatic Carcinoma in Elderly Patients.
    Yang J; Xu Z; Zhang J; Zheng Y; Gu J; Zhou Q; Wang X; Guo S; Zhang H; Chen S; Wang H
    Med Sci Monit; 2022 Nov; 28():e938443. PubMed ID: 36404606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.